Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREGAnne Zaremba, Lisa Zimmer, Patrick Terheyden et al.|European Journal of Cancer|2023Cited by 13
First-line checkpoint inhibitor therapy in metastatic acral lentiginous melanoma compared to other types of cutaneous melanoma: A multicenter study from the prospective skin cancer registry ADOREGSören Reinhard, Henner Stege, Jochen Utikal et al.|European Journal of Cancer|2025Cited by 4
Presence of brain metastasis differentially impacts long-term survival after first-line therapy in melanoma depending on BRAF mutation statusJan‐Malte Placke, Selma Ugurel, Luisa Sophie Rajcsanyi et al.|Frontiers in Immunology|2025Cited by 2